Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd – Trademark Portfolio
Entity Type: 99
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include SERBECOM. The owner is based in Shenzhen.
B1, 6th Floor, Building 7, Lehui Science and Technology Innovation Center
No. 489 Jihua Road, Bantian Community, Bantian Street, Longgang District
Shenzhen 518000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd have?
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd file in?
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd's most well-known trademarks?
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd's registered trademark portfolio includes well-known marks such as SERBECOM. These are among 1 currently registered trademark in the portfolio.
What is Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd's trademark registration success rate?
Shenzhen Xiangsheng Nuoen Biotechnology Co., Ltd has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.